An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A handful of new reports and discussions are asking a simple question: which of the new weight-loss drugs quiets the "food noise" — that inner hunger, cravings, or constant thinking about eating — the most? The conversation compares three medicines you may have heard about: semaglutide (the main ingredient in Ozempic/Wegovy), tirzepatide (Zepbound/Mounjaro), and a newer experimental drug called retatrutide. People are sharing study results and personal impressions trying to rank how well each drug reduces appetite and food-related thoughts. Semaglutide is a drug that acts like a natural gut hormone that signals fullness to the brain and slows stomach emptying. That is why people on it often say they feel less hungry and get full faster. Tirzepatide works on two related hormones (it’s a dual agonist), so it combines that fullness signal with another pathway that affects blood sugar and appetite. Retatrutide is an experimental compound that hits three hormonal pathways (a triple agonist), so it’s designed to be even stronger at turning down hunger and boosting weight loss — but it’s newer and less tested in people. What the studies actually show varies. Semaglutide and tirzepatide have large clinical trials in hundreds to thousands of people that show meaningful weight loss and reduced appetite compared with placebo. The differences between semaglutide and tirzepatide in reducing food preoccupation exist but are not huge in most trials — tirzepatide often produces slightly greater average weight loss and appetite reduction. Retatrutide’s data so far comes from much smaller, early-stage human studies and animal work; those early results look promising, sometimes showing bigger drops in hunger and faster weight loss, but the numbers are from limited samples and short follow-up. In plain terms: longer, larger trials support semaglutide and tirzepatide; retatrutide might be stronger but it’s still experimental. Why this matters is practical. For someone who struggles with constant thoughts about food or strong cravings, a drug that reliably reduces that mental noise can be life-changing — it can make it easier to stick to a diet, reduce bingeing, and lose weight. Doctors and patients will weigh effectiveness, side effects, cost, and availability when choosing between options. Right now, more people and clinicians have real-world experience with semaglutide and tirzepatide, while retatrutide may be an option years ahead if ongoing trials confirm safety and superior benefit. There are important caveats. All these medicines can cause side effects like nausea, diarrhea, constipation, and rarely more serious problems. They don’t “cure” obesity; symptoms often return if the drug is stopped. Retatrutide is experimental — not approved yet — so its long-term safety and exact benefits are uncertain. People with certain medical conditions or those on other medications need medical advice before starting any of these drugs. Cost and insurance coverage are practical barriers for many. Bottom line: semaglutide and tirzepatide both lower food-related thoughts and cravings with good evidence; retatrutide looks promising for a bigger effect but needs larger, longer human trials to be sure.
Source: r/Semaglutide